secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001628280-26-024336
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics enters Roche DAC collaboration; $20M upfront, >$1B milestones
-----------------------------------------------------------------------------

- $20M upfront from Roche for two DAC programs targeting undisclosed oncology targets.
- Eligible for over $1B in discovery, regulatory, and commercial milestones plus tiered royalties (mid-single to low-double digit).
- Roche responsible for all development, regulatory, manufacturing, and commercialization costs.
- Option for a third target with additional payment, milestones, and royalties.
- Leverages C4T's TORPEDO platform for degrader payloads and Roche's ADC expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026024336/0001628280-26-024336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026024336/cccc-20260409.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-024336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer